DK1816204T3 - Rekombinant adenovirus af Ad26-serotypen - Google Patents

Rekombinant adenovirus af Ad26-serotypen

Info

Publication number
DK1816204T3
DK1816204T3 DK07106044.6T DK07106044T DK1816204T3 DK 1816204 T3 DK1816204 T3 DK 1816204T3 DK 07106044 T DK07106044 T DK 07106044T DK 1816204 T3 DK1816204 T3 DK 1816204T3
Authority
DK
Denmark
Prior art keywords
serotypes
adenovirus
tropism
proteins
natural
Prior art date
Application number
DK07106044.6T
Other languages
English (en)
Inventor
Ronald Vogels
Abraham Bout
Menzo Jans Emko Havenga
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1816204(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK1816204T3 publication Critical patent/DK1816204T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07106044.6T 1999-05-17 2000-05-16 Rekombinant adenovirus af Ad26-serotypen DK1816204T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201545 1999-05-17
EP04077434A EP1550722B1 (en) 1999-05-17 2000-05-16 Recombinant human adenovirus serotype 35

Publications (1)

Publication Number Publication Date
DK1816204T3 true DK1816204T3 (da) 2011-01-24

Family

ID=8240209

Family Applications (6)

Application Number Title Priority Date Filing Date
DK07106044.6T DK1816204T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus af Ad26-serotypen
DK00201738.2T DK1054064T4 (da) 1999-05-17 2000-05-16 Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35
DK07106036.2T DK1818408T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus af serotypen Ad11
DK07106054.5T DK1816205T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus på grundlag af serotypen Ad48
DK05077719T DK1681353T3 (da) 1999-05-17 2000-05-16 Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
DK04077434T DK1550722T3 (da) 1999-05-17 2000-05-16 Rekombinant human adenovirus serotype 35

Family Applications After (5)

Application Number Title Priority Date Filing Date
DK00201738.2T DK1054064T4 (da) 1999-05-17 2000-05-16 Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35
DK07106036.2T DK1818408T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus af serotypen Ad11
DK07106054.5T DK1816205T3 (da) 1999-05-17 2000-05-16 Rekombinant adenovirus på grundlag af serotypen Ad48
DK05077719T DK1681353T3 (da) 1999-05-17 2000-05-16 Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
DK04077434T DK1550722T3 (da) 1999-05-17 2000-05-16 Rekombinant human adenovirus serotype 35

Country Status (14)

Country Link
EP (6) EP1681353B1 (da)
JP (2) JP4843145B2 (da)
KR (1) KR100741247B1 (da)
AT (6) ATE519855T1 (da)
AU (1) AU777041B2 (da)
CA (1) CA2372655C (da)
CY (4) CY1106762T1 (da)
DE (4) DE60045138D1 (da)
DK (6) DK1816204T3 (da)
ES (5) ES2372823T3 (da)
IL (3) IL146479A0 (da)
NZ (1) NZ515582A (da)
PT (5) PT1816204E (da)
WO (1) WO2000070071A1 (da)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (en) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gene delivery vectors provided with a tissue tropism for T-lymphocytes
AU6368901A (en) 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
AU2002223556A1 (en) * 2000-09-20 2002-04-02 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
AU2002211087A1 (en) * 2000-10-06 2002-04-15 Crucell Holland B.V. Gene delivery vectors for stem cells
EP1195440A1 (en) * 2000-10-06 2002-04-10 Introgene B.V. Gene delivery vectors for stem cells
DE60234496D1 (de) * 2001-01-04 2010-01-07 Goeran Wadell Virusvektor zur gentherapie
JP2004536572A (ja) 2001-02-23 2004-12-09 セル・ジェネシス・インコーポレイテッド 新規ベクター構築物
AU2003210661A1 (en) * 2002-01-24 2003-09-02 Novartis Ag Fiber shaft modifications for efficient targeting
EA010828B1 (ru) * 2002-04-25 2008-12-30 Круселл Холланд Б.В. Рекомбинантный аденовирусный вектор и способы его получения и применения
CN100374574C (zh) 2002-04-25 2008-03-12 克鲁塞尔荷兰公司 稳定的腺病毒载体及其增殖方法
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
NZ539813A (en) * 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
CN1934253A (zh) * 2003-07-18 2007-03-21 昂尼克斯药物公司 用于治疗疾病的b亚组腺病毒载体
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
CN1972958B (zh) * 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
RU2448157C2 (ru) 2004-05-26 2012-04-20 Псиоксус Терапьютикс Лимитед Химерные аденовирусы для применения для лечения злокачественного новообразования
US7741099B2 (en) 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
CN102220357B (zh) 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
AU2006271666B2 (en) 2005-07-22 2011-04-07 Crucell Holland B.V. Cell line for producing coronaviruses
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
CA2770075C (en) 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
US20120315696A1 (en) * 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2867955C (en) 2012-03-22 2023-02-07 Crucell Holland B.V. Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
JP6162224B2 (ja) 2012-05-24 2017-07-12 クルセル ホランド ベー ヴェー 血管組織の形質導入のためのアデノウイルスベクター
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
JP6333814B2 (ja) 2012-07-10 2018-05-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マイコバクテリア抗原ワクチン
WO2014078688A2 (en) 2012-11-16 2014-05-22 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
EA034653B1 (ru) 2013-06-17 2020-03-03 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv перед слиянием
NZ718931A (en) 2013-10-25 2022-10-28 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
SG11201701745TA (en) 2014-09-03 2017-04-27 Bavarian Nordic As Methods and compositions for enhancing immune responses
DK3656395T5 (da) 2014-09-03 2024-05-27 Janssen Vaccines & Prevention Bv Fremgangsmåder og sammensætninger til at inducere beskyttende immunitet mod filovirusinfektion
PL3197489T3 (pl) 2014-09-26 2021-11-08 Beth Israel Deaconess Medical Center, Inc. Sposoby i kompozycje do indukowania ochronnej odporności przeciwo zakażeniu ludzkim wirusem niedoboru odporności
MX2017005788A (es) 2014-11-04 2017-08-02 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el vph16.
PL3283634T3 (pl) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
EP3288573B1 (en) 2015-04-30 2020-02-12 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
CA2995740A1 (en) 2015-08-20 2017-02-23 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
MD3584252T2 (ro) 2015-12-15 2022-01-31 Janssen Vaccines & Prevention Bv Antigene, vectori, compoziții ale virusului imunodeficienței umane și metode de utilizare a acestora
EP3389682B1 (en) 2015-12-17 2021-11-17 Psioxus Therapeutics Limited Group b adenovirus encoding an anti-tcr-complex antibody or fragment
CN108699566B (zh) 2016-02-23 2023-06-30 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
HUE053027T2 (hu) 2016-04-05 2021-06-28 Janssen Vaccines & Prevention Bv Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
ES2836598T3 (es) 2016-05-30 2021-06-25 Janssen Vaccines & Prevention Bv Proteínas F de RSV prefusión estabilizadas
SG11201810549TA (en) 2016-06-16 2018-12-28 Janssen Vaccines & Prevention Bv Hiv vaccine formulation
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018011198A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3503918B1 (en) 2016-08-29 2020-09-30 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CN110958887B (zh) 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
EA202090738A1 (ru) 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
WO2019099970A1 (en) 2017-11-20 2019-05-23 Janssen Pharmaceuticals Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
EP3723771A4 (en) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. RECOMBINANT ADENOVIRUS AND THEIR USES
WO2019123250A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
EP3810277A1 (en) 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
MX2021008392A (es) 2019-01-10 2021-10-26 Janssen Biotech Inc Neoantígenos prostaticos y sus usos.
KR20220008816A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
EP3969044A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
PE20221182A1 (es) 2019-11-18 2022-08-05 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
CN111337042B (zh) * 2020-03-13 2021-11-02 湖北大学 一种车辆路径规划方法及系统
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CA3188801A1 (en) 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
EP4267605A2 (en) 2020-12-23 2023-11-01 Janssen Biotech, Inc. Neoantigen peptide mimics
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
JP4683727B2 (ja) * 1999-03-04 2011-05-18 クルーセル ホランド ベスローテン フェンノートシャップ 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法
JP2011521985A (ja) * 2008-06-03 2011-07-28 オカイロス アーゲー Ｈｃｖ感染の予防および治療のためのワクチン

Also Published As

Publication number Publication date
NZ515582A (en) 2003-11-28
JP5335037B2 (ja) 2013-11-06
ES2354578T3 (es) 2011-03-16
EP1818408A1 (en) 2007-08-15
DE60045138D1 (de) 2010-12-02
DK1054064T4 (da) 2010-05-03
CA2372655C (en) 2011-11-15
EP1054064B1 (en) 2004-10-06
DK1816205T3 (da) 2011-11-21
EP1816205B1 (en) 2011-08-10
DK1818408T3 (da) 2011-10-17
PT1550722E (pt) 2007-09-25
IL214413A0 (en) 2011-09-27
ATE364707T1 (de) 2007-07-15
EP1681353A1 (en) 2006-07-19
JP2002543846A (ja) 2002-12-24
EP1818408B1 (en) 2011-08-10
EP1681353B1 (en) 2009-10-07
KR100741247B1 (ko) 2007-07-19
EP1816204B1 (en) 2010-10-20
DE60014489D1 (de) 2004-11-11
CA2372655A1 (en) 2000-11-23
JP2011224014A (ja) 2011-11-10
EP1054064B2 (en) 2009-12-16
CY1112008T1 (el) 2015-11-04
IL214413A (en) 2014-04-30
ATE485382T1 (de) 2010-11-15
AU777041B2 (en) 2004-09-30
CY1106762T1 (el) 2012-05-23
ATE278792T1 (de) 2004-10-15
DE60035229D1 (de) 2007-07-26
EP1550722A1 (en) 2005-07-06
CY1111494T1 (el) 2015-08-05
IL146479A0 (en) 2002-07-25
ES2372824T3 (es) 2012-01-26
DE60014489T2 (de) 2005-11-24
EP1550722B1 (en) 2007-06-13
DE60014489T3 (de) 2010-08-12
AU4954700A (en) 2000-12-05
ES2289426T3 (es) 2008-02-01
PT1054064E (pt) 2005-02-28
EP1816205A1 (en) 2007-08-08
DE60035229T2 (de) 2008-02-21
IL146479A (en) 2011-12-29
ATE519854T1 (de) 2011-08-15
PT1816204E (pt) 2011-01-24
CY1112189T1 (el) 2015-12-09
EP1054064A1 (en) 2000-11-22
DK1681353T3 (da) 2010-01-04
DE60043126D1 (de) 2009-11-19
EP1816204A1 (en) 2007-08-08
PT1818408E (pt) 2011-11-15
PT1816205E (pt) 2011-11-15
ES2231103T5 (es) 2010-04-15
ES2231103T3 (es) 2005-05-16
JP4843145B2 (ja) 2011-12-21
KR20020028879A (ko) 2002-04-17
ATE519855T1 (de) 2011-08-15
DK1054064T3 (da) 2005-01-10
ATE445018T1 (de) 2009-10-15
WO2000070071A1 (en) 2000-11-23
DK1550722T3 (da) 2007-10-08
ES2372823T3 (es) 2012-01-26

Similar Documents

Publication Publication Date Title
DK1816204T3 (da) Rekombinant adenovirus af Ad26-serotypen
NZ336829A (en) Adenoviruses having altered hexon proteins which present epitopes that are not recognised by neutralizing antibodies to the unmodified adenovirus of another serotype
EE05538B1 (et) Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine
NO20020276D0 (no) In vitro seleksjon og valgfri identifikasjon av polypeptider ved bruk av fast-fase b¶rere
DE60000008D1 (de) Belüftete Scheibe für Scheibenbremse
DK1762145T3 (da) Teksturerede cellulose- og lignocellulosematerialer og sammensætninger og kompositmaterialer fremstillet ud fra disse
JP2002537816A5 (da)
JP2008508899A5 (da)
WO2002018948A3 (en) Differentially expressed epitopes and uses thereof
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
EP1270586A3 (de) Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
AU2001284511A1 (en) Impartment of virus-resistance with the use of plant protein binding to plant virus transport protein
NO20021634D0 (no) Fremstilling av rekombinante adenoviruser og adenovirusbanker
坂口実 TWO-PERSON HI-LO POKER: STUD AND DRAW, II
Takasaki et al. Euglobals-In-2 and-In-3, new euglobals from Eucalyptus incrassata
WO2002083902A3 (en) Adenovirus serotype 30 (ad30) fiber protein and uses thereof
Chul-Sa et al. 14-DeoxyparsonsianidineN-Oxide: A Pyrrolidine Alkaloid Sequestered by the Giant Danaine Butterfly, Idea leuconoe
Amin Ad5 and Ad3 chimeric fiber travels into the cell without the CAR
Honami et al. Involvement of Ovotransferrin in the Thermally Induced Gelation of Egg White at around 65℃
Strauss et al. Till Eulenspiegels lustige Streiche: op. 28: symphonic poem; Metamorphosen: a study for 23 solo strings: Av. 142; Tod und Verklärung: op. 24: symphonic poem
Asgharian et al. A comparative monomolecular film study of 1, 2-di-O-palmitoyl-3-O-(. alpha.-and. beta.-D-glucopyranosyl)-sn-glycerols [Erratum to document cited in CA111 (11): 92542q]
Strauss et al. Also sprach Zarathustra: Op. 30. Totenfeier
WO2004011489A3 (fr) Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes
SE0003450D0 (sv) Sams bank-betalkort
IT251761Y1 (it) Telaio articolato per pattini, sci da fondo o simili